Mayukh Sukhatme Sells 311,873 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 311,873 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $21.74, for a total value of $6,780,119.02. Following the transaction, the insider directly owned 19,273,032 shares in the company, valued at $418,995,715.68. The trade was a 1.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Mayukh Sukhatme also recently made the following trade(s):

• On Wednesday, December 31st, Mayukh Sukhatme sold 1,018,995 shares of Roivant Sciences stock. The stock was sold at an average price of $21.71, for a total transaction of $22,122,381.45.
• On Wednesday, December 17th, Mayukh Sukhatme sold 26,831 shares of Roivant Sciences stock. The shares were sold at an average price of $23.09, for a total transaction of $619,527.79.

Roivant Sciences Trading Up 0.3%

Shares of ROIV traded up $0.07 on Wednesday, reaching $21.70. The company’s stock had a trading volume of 5,645,046 shares, compared to its average volume of 7,953,955. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $23.47. The firm has a fifty day moving average of $20.80 and a 200-day moving average of $15.71.

Institutional Investors Weigh In On Roivant Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Allworth Financial LP lifted its position in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares in the last quarter. Swiss Life Asset Management Ltd purchased a new stake in Roivant Sciences during the 3rd quarter worth about $217,000. Danske Bank A S bought a new position in Roivant Sciences in the 3rd quarter worth about $138,000. XTX Topco Ltd bought a new stake in shares of Roivant Sciences during the third quarter valued at about $1,067,000. Finally, Alyeska Investment Group L.P. increased its position in shares of Roivant Sciences by 326.7% during the third quarter. Alyeska Investment Group L.P. now owns 494,455 shares of the company’s stock valued at $7,481,000 after buying an additional 378,589 shares during the period. Institutional investors own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ROIV. Jefferies Financial Group raised their price objective on Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, September 18th. Citigroup lifted their target price on shares of Roivant Sciences from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. The Goldman Sachs Group increased their price target on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Leerink Partners boosted their price objective on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Finally, Weiss Ratings upgraded Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Saturday, October 25th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $25.19.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.